Evidence map›Paper›PMID 41930338›Full record

ArticleMedComm2026

Pablo Cano-Ramírez, Marta Toledano-Fonseca, María Teresa Cano-Osuna, Nerea Herrera-Casanova, Emilio Carrillo-Pecero, Antonio Rodríguez-Ariza, Enrique Aranda, María Victoria García-Ortiz

Abstract read
In one paragraph

Article in MedComm, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Pablo Cano-RamírezUniversity of Córdoba Córdoba Spain.ORCID https://orcid.org/0009-0006-0746-4037
Marta Toledano-FonsecaUniversity of Córdoba Córdoba Spain.ORCID https://orcid.org/0000-0002-1997-9197
María Teresa Cano-OsunaUniversity of Córdoba Córdoba Spain.ORCID https://orcid.org/0000-0002-4732-0322
Nerea Herrera-CasanovaUniversity of Córdoba Córdoba Spain.ORCID https://orcid.org/0009-0004-5362-7349
Emilio Carrillo-PeceroUniversity of Córdoba Córdoba Spain.
Antonio Rodríguez-ArizaUniversity of Córdoba Córdoba Spain.ORCID https://orcid.org/0000-0001-5304-5745
Enrique ArandaUniversity of Córdoba Córdoba Spain.ORCID https://orcid.org/0000-0002-5471-2842
María Victoria García-OrtizUniversity of Córdoba Córdoba Spain.ORCID https://orcid.org/0000-0001-6527-4908

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pancreatic cancer remains highly lethal, largely due to late diagnosis and limited efficacy of treatments. Improving first-line treatment selection and patient monitoring requires novel, non-invasive biomarkers beyond carbohydrate antigen 19-9 (CA19-9) and imaging. This study investigates epigenetic biomarkers from liquid biopsy with prognostic and predictive potential in metastatic pancreatic ductal adenocarcinoma (PDAC; mPDAC). Genome-wide methylation profiling of cell-free DNA (cfDNA) from healthy individuals and stage IV mPDAC patients identified 13 gene-associated CpG sites with significantly altered methylation patterns. ddPCR validation confirmed consistent methylation differences in lymphocyte transmembrane adaptor 1 (

Indexed as

DNA methylation and response predictionliquid biopsypancreatic ductal adenocarcinoma

Identifiers

PMID41930338
PMCPMC13042955

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.